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Abstract: Molecular stratiﬁ  cation of disease based on expression levels of sets of genes can help guide therapeutic decisions 
if such classiﬁ  cations can be shown to be stable against variations in sample source and data perturbation. Classiﬁ  cations 
inferred from one set of samples in one lab should be able to consistently stratify a different set of samples in another lab. 
We present a method for assessing such stability and apply it to the breast cancer (BCA) datasets of Sorlie et al. 2003 and 
Ma et al. 2003. We ﬁ  nd that within the now commonly accepted BCA categories identiﬁ  ed by Sorlie et al. Luminal A and 
Basal are robust, but Luminal B and ERBB2+ are not. In particular, 36% of the samples identiﬁ  ed as Luminal B and 55% 
identiﬁ  ed as ERBB2+ cannot be assigned an accurate category because the classiﬁ  cation is sensitive to data perturbation. 
We identify a “core cluster” of samples for each category, and from these we determine “patterns” of gene expression that 
distinguish the core clusters from each other. We ﬁ  nd that the best markers for Luminal A and Basal are (ESR1, LIV1, 
GATA-3) and (CCNE1, LAD1, KRT5), respectively. Pathways enriched in the patterns regulate apoptosis, tissue remodel-
ing and the immune response. We use a different dataset (Ma et al. 2003) to test the accuracy with which samples can be 
allocated to the four disease subtypes. We ﬁ  nd, as expected, that the classiﬁ  cation of samples identiﬁ  ed as Luminal A and 
Basal is robust but classiﬁ  cation into the other two subtypes is not. 
Keywords: Breast cancer, Clusters, Patterns, Multi-gene Biomarkers, Diagnosis. 
Introduction
Breast cancer (BCA) is a common and heterogeneous disease affecting women of all ages. Its occur-
rence is correlated with levels of estrogen (ER), progesterone (PR) and Her2neu (ERBB2) (Gruvberger 
et al. 2001; Lacroix and Leclercq 2005). Clinically, BCA is classiﬁ  ed into two major subtypes: ER+ 
and ER-. These groups are sometimes stratiﬁ  ed further by ERBB2 and/or PR levels. Across all treat-
ments, ER+ and/or PR+ patients have a better prognosis than ER- and/or PR- tumors (Anim et al. 2005) 
and are also more likely to respond to hormone therapy (e.g. tamoxifen). Over-expression of ERBB2, 
seen in 25–30% of cases, is often a marker of aggressive disease, poor prognosis and mixed treatment 
results (Diermeier et al. 2005).
In spite of sustained research and medical and pharmaceutical effort, the incidence and death rate of 
BCA remains high. In 2005, more than 1.2 million new cases were diagnosed world wide and more than 
20% of these will die from the disease (http://imaginis.com/breasthealth/). A major cause of treatment 
failure is that tumors with similar histopathology have divergent clinical courses and prognoses. The 
goal of the present study is the same as that of many others (Bieche et al. 1995; West et al. 2001; van’t 
Veer et al. 2002; Honig et al. 2004; Ahnstrom et al. 2005;  Sharma et al. 2005; Osipo et al. 2005), that 
molecular proﬁ  ling of BCA will clarify molecular correlates of disease, and this in turn will improve 
choice of therapy, and provide leads to new and more effective therapeutics. 
In a series of papers on analysis of cDNA data of BCA tissue samples (Sorlie et al. 2001; Perou 
et al. 2000, 2001) the samples were uniquely assigned to one of four distinct categories: Luminal A, 
Luminal B, ERBB2+ (or Her2+) and Basal-like. These subtypes were later validated by Sotiriou et al. 
2003, Loi et al. 2005 and Kristensen et al. 2005. The ﬁ  rst two categories were mostly ER+ and the latter 
two mostly ER– negative. In the original analysis of Perou et al. 2000, Basal tumors were characterized 
by high levels of keratins 5 and 17, laminin, and fatty acid binding protein 7 genes (see also Charafe-Cancer Informatics Online 2006: 2 244
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Jauffret et al. 2005), whereas ERBB2+ was char-
acterized by high levels of several genes in the 
ERBB2 amplicon at 17q12.21 including ERBB2 
and GRB7. Other studies identified different 
markers (Abd El-Rehim et al. 2005; Bertucci et al. 
2005; Farmer et al. 2005; Hu et al. 2006; Sorlie 
et al. 2006) and a consensus set of markers for all 
BCA patients is not currently available. 
Luminal and Basal-like tumors arise in distinct 
breast tissue cell types (Perou et al. 2000) and 
have very different disease course (Sorlie et al. 
2001, 2003) and response to therapeutics (Troester
et al. 2004; Bertucci et al. 2005). The Luminal A 
subtype has the best overall prognosis followed by 
Luminal B while the other two subtypes are more 
aggressive and difﬁ  cult to treat. The nomencla-
ture of these subtypes has found its way into the 
language and culture of clinical practice and affects 
treatment options offered to patients. This makes 
it important to validate the stability of the original 
classiﬁ  cation of Sorlie et al. This is the main goal 
of the present paper.
The original analysis used simple hierarchical 
clustering (Eisen et al. 1998) which is known to be 
sensitive to data perturbation (Monti et al. 2003; 
van der Kloot et al. 2005). We re-analyzed the 
data using a robust averaging procedure to access 
the stability of imposing ﬁ  ve clusters (4 disease 
subtypes + Normal) on the data. The goal was to 
identify a “core” set of samples in each subtype 
which were stable under data perturbations, and 
to use these cores to determine “patterns” of gene 
expression for each core. We found stable core 
clusters for samples in the Luminal A, Basal and 
Normal clusters of the original analysis. However, 
the “Luminal B” and “ERBB2+” clusters of
Sorlie et al. were unstable, with only a subset of the 
samples from the previous assignment remaining in 
stable core clusters under data perturbation. Instead, 
the originally assigned samples scattered over two 
or more clusters. This suggests that the Luminal 
B and ERBB2+ clusters (and their markers) as 
identiﬁ  ed in Sorlie et al. 2003, are unstable to data 
perturbation and need further analysis. 
For the Luminal A and Basal categories, we ﬁ  nd 
a robust set of gene markers and patterns. If we 
combine the Sorlie et al. dataset with a new dataset 
from Ma et al. and cluster the combined data using 
these robust gene markers and patterns, then in the 
new data, we can assign a robust subtype label 
for Luminal A and Basal but not for the other two 
disease phenotypes. 
Materials and Methods 
Datasets
Data 1: The cDNA dataset of (Sorlie et al. 2003) 
was obtained from http://genome-www.stanford.
edu/breast_cancer/robustness/data/SupplText.
html. The data had expression levels of N = 552 
genes for M = 122 samples of which 112 were 
from BCA patients and 10 controls. The 552 genes 
were selected by Sorlie et al. to have small varia-
tion in tissue samples from the same patient and 
a high variation in tissue samples from different 
patients.
Data 2: The Ma et al. dataset was downloaded 
from www.geneexpression_ma.org. It consisted 
of expression levels of 1940 genes for 93 samples 
micro-dissected from 36 BCA patients and 3 
normals. The samples were from three stages 
of disease: atypical ductal hyperplasia or ADH, 
ductal carcinoma in situ or DCIS and invasive 
ductal carcinoma or IDC respectively. The genes 
made available in the data were chosen by linear 
discriminant analysis as markers for breast cancer 
progression. ER, PR and HER2neu levels measured 
through immunohistochemistry were available. 
Preprocessing and Imputation 
for Data 1 
The matrix of samples (columns) and genes (rows) 
was normalized to mean 0 and variance 1 ﬁ  rst 
across columns and then across rows, ignoring 
missing entries. The matrix had 5,027 missing 
entries. We ﬁ  rst eliminated genes and samples with 
more than 20% missing entries. This reduced the 
data to N = 530 genes and M = 118 samples. We 
imputed the missing entries using a simple gener-
alization of the kNN method of Troyanskaya et al. 
2001 as follows:
We identiﬁ  ed the k nearest neighbor entries for 
missing entry xi j using the Euclidean metric,
 
 
     (, ) ( ( ) ) dii x x
/
ij ij j
2
12 =- l l !     
with the requirement that the genes chosen as 
nearest neighbors have at least t% ﬁ  lled entries. 
Twenty imputations were done at each xi j using 
the range 10 ≤ k ≤ 14 for k and varying t from 50% 
to 80% in increments of 10. Let {x1, x2, …, xk} be 
the k-nearest neighbor entries in increasing order 
of distance and R be a uniform random number in 
(0,1). Then the imputed value Cancer Informatics Online 2006: 2 245
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y is given by y = xj, which satisﬁ  es 
  X
xi
i
j
1
1
=
-
!  < R ≤ X
xi
i
j
1 = ! , 
 
where X = xi
i
k
1 = ! .
 
Twenty datasets were generated in this way, one 
for each (k,t) value. The clustering was averaged 
over these twenty datasets in order to create a set 
of clusters insensitive to parameter choice in data 
imputation. This averaging is an improvement over 
the kNN method because it is stable to both varia-
tion in k and variation in how the neighbors are 
chosen (as measured by t). Multiple clones in the 
data were eliminated by averaging after discarding 
outliers outside a 95% conﬁ  dence interval. This 
process left 523 genes with no missing entries or 
clones. The ﬁ  nal data is given in Supplementary 
Table 1.
Results 
Identifying “Core” Clusters
We use the letters A, B, C, D, E to denote the ﬁ  ve 
phenotypes: Luminal A, Luminal B, ERBB2+, 
Basal, and Normal respectively. The clusters were 
identiﬁ  ed using the consensus hierarchical clus-
tering technique of Monti et al. 2003 implemented 
in GenePattern (http://www.broad.mit.edu/cancer/
software/genepattern/). This method assesses the 
stability of hierarchical clustering across multiple 
perturbations of the data. We generated 100 copies 
of the dataset by randomly selecting 80% of the 
samples. Each copy was hierarchically clustered 
using a Euclidean distance metric and the top 5 
clusters were selected. For each distinct sample 
pair (i, j) in the data, we computed the frequency 
Fij with which the pair clustered together over the 
100 copies of the datasets. The matrix of Fij values 
is called the “agreement matrix.” Repeating this for 
all 20 data imputations and averaging gave the ﬁ  nal 
“consensus agreement matrix” which is shown in 
Supplementary Table 2. 
The five core clusters were identified as 
bicliques (Alexe et al. 2004) using the agreement 
matrix entries as a measure of similarity. We used 
the criterion that two samples have the same pheno-
type and belong to the same core cluster if they 
have a consensus agreement matrix score greater 
than P. For the Luminal A and Basal subtypes, the 
value P = 90% was sufﬁ  cient to get an exact match 
between the core cluster identiﬁ  ed by us and the 
assignment in Perou et al. 2000 and Sorlie et al. 
2003. However, for samples assigned to Luminal B 
and ERBB2+ by the earlier study, these thresholds 
needed to be lowered to 50% and 25% respectively 
to get agreement with the previous assignments, 
suggesting that these categories are considerably 
less stable to data perturbation. The ﬁ  ve core clus-
ters contained 60 out of the 118 samples.
From the Fij values, we deﬁ  ne the average agree-
ment score between a sample i and other samples 
j in a given cluster C as
       
  F n
F
, iC
ij
j
n
1 =
= !
 , 
where j  =  1, ... , n, and n is the number of samples 
in the cluster C. Fi,C was calculated for each 
of the ﬁ  ve clusters. The results are shown in 
Figures 1 a–e. For each phenotype, we used a 
cutoff criterion on Fi,C to assign it to the corre-
sponding core cluster and these samples are 
shown in color. Many samples earlier identiﬁ  ed 
as Luminal B also have a high score in our Basal 
core cluster (Figure 1b and 1d). This suggests 
that the Luminal B identiﬁ  cation is problematic. 
Figure 1e also shows that some samples identiﬁ  ed 
earlier as Luminal A are placed in our “Normal” 
core cluster, suggesting that these patients may 
have minimal disease. Overall, our analysis shows 
that Luminal A, Basal and Normal phenotypes 
are robustly classiﬁ  able into homogeneous clus-
ters but Luminal B and ERBB2+ do not cluster 
well. We ﬁ  nd that 36% of the samples previously 
placed in the Luminal B category and 55% of 
samples previously classiﬁ  ed as ERBB2+ are in 
fact ambiguous; i.e., their assignments are highly 
sensitive to data perturbation and they should be 
reanalyzed or classiﬁ  ed as ambiguous. The scores 
of some unclassiﬁ  ed samples in Sorlie et al. 2003 
are shown in Figure 1f. For the samples where 
these scores are higher than the cutoff in one core 
cluster but not in any other, the corresponding 
sample can be assigned a category label by our 
clustering. 
Table 1 compares the original assignments of 
Sorlie et al. with our core clusters of Figure 1 and 
shows the sample id’s from the original study. Cancer Informatics Online 2006: 2 246
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The agreement fraction between the original 
assignment and our assignments is highest for the 
Normal, Luminal A and Basal categories and lower 
in the other two phenotypes. 
For each sample i in a core cluster, we also 
calculated the silhouette score (Rousseeuw,1987) 
deﬁ  ned by 
 s (i) =  () (( ) ,( )
() ()
max si ai bi
bi ai = -  , 
where a(i) is the average dissimilarity between i 
and all other samples in the cluster, and b(i) is the 
minimum average dissimilarity of i to all samples 
in other clusters. If s(i) values in a cluster are close 
to unity, the cluster is well deﬁ  ned. An s(i) value 
near zero indicates that the sample is between 
two clusters. Negative values of s(i) mean that 
the sample is in the wrong cluster. The “silhou-
ette width” of a cluster is the average of the s(i) 
scores of all samples in that cluster. The silhouette 
widths for our core clusters as well as for the Sorlie 
et al. clusters are given in Table 1. The low values 
of the average silhouette scores are worrisome. 
They suggest either that the stratiﬁ  cation into these 
phenotypes is problematic or that a better choices 
of genes is necessary to separate the phenotypes 
more reliably.
Identifying Robust Gene Markers 
Microarray datasets suffer from an overabundance 
of genes, most of which do not contribute to the 
signal. Identifying differentially expressed genes 
for a given set of phenotypes is a difﬁ  cult problem 
for which many methods have been proposed. 
These can be divided into two major groups 
(Guyon and Ellisseeff, 2003, Inza et al. 2004, 
Lai et al. 2006, Jeffery et al. 2006) for supervised 
learning:
(i) Filtering or Variable Ranking methods: 
These select features based on quality scores. They 
include the fold change test (e.g. Mutch et al. 2002; 
Breitling and Herzyk, 2005), the t-test (Gossett, 
1908, Tusher et al. 2001), the Wilcoxon-Mann-
Whitney test (Bradley, 1968; Lehman, 1975), 
the Signal-to-Noise Ratio (SNR) test (Golub 
et al. 1999), the J5 test (Patel and Lyons-Weiler, 
2004), the D1 test (Patel and Lyons-Weiler, 2004) 
etc. Another set of methods measure the "sepa-
rability" of data into different phenotype classes. 
These include simple separability (Patel and 
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Lyons-Weiler, 2004), weighted separability (Patel 
and Lyons-Weiler, 2004), envelope eccentricity 
(Alexe et al. 2006), separation measure (Alexe 
et al. 2006b) etc. A third class uses information-
theoretic methods such as the entropy criterion 
(e.g. Furlanello et al. 2003; Liu et al. 2005), mutual 
information (e.g. Tourassi et al. 2001), information 
gain (Liu, 2004) etc. Finally, there are the statistical 
impurity measures (Su et al. 2003) which include 
the two-ing rule, the Gini index, max-minority, 
sum-minority, sum-of-variances etc.
(ii) Feature Subset Selection Methods: One such 
method selects those features which are useful for 
classiﬁ  cation for a given machine learning algo-
rithm (e.g. SVM (Vapnik, 1998), ANN (Bishop, 
1995), kNN (Ripley, 1996) etc). More sophisti-
cated approaches are embedded methods which 
include the selection of features as part of the 
training process for the classiﬁ  er. These methods 
are computationally intensive and require efﬁ  cient 
search strategies or a preliminary ﬁ  ltering of the 
non-reliable genes to reduce the dimensionality of 
the problem.
The existence of such a variety of feature selec-
tion methods poses a challenge in microarray 
data analysis. There have been recent attempts to 
combine various approaches into a meta selec-
tion procedure based on "majority-voting" using 
ranking by predictive content across many data 
perturbations and machine learning methods (e.g. 
Bhanot et al. 2005; Alexe et al. 2005a). Several 
studies (Guyon and Ellisseeff, 2001; Alexe et al. 
2005b) have shown that variables which are only 
weakly correlated with phenotype are very useful 
when used in combinations. This principle has lead 
to the development and study of combinatorial 
markers or patterns (Crama et al. 1988; Bhanot 
et al. 2005; Alexe et al. 2006b).
In the present study, we have chosen to use a 
single feature selection method (namely the SNR 
test, Golub et al. 1999) which has been shown 
(Alexe et al. 2006b) to have good performance on 
genomic and proteomic data. However, we cannot 
guarantee that it is the best method, particularly 
because of the need to impute the missing data in 
the dataset of Sorlie et al. As an added check on 
the feature selection, we also use the combinatorial 
“pattern” method and averaging over data pertur-
bations to reduce the errors from potentially “less 
than optimum” choice of features. 
We identiﬁ  ed a large pool of uni-gene markers 
for each core that distinguish it from the others 
using the signal-to-noise statistic. For gene i, if 
μ1(i) and μ2(i) be the average gene expression 
levels for the core and its complement and σ1(i) 
and σ2(i) the corresponding standard deviations, 
the signal-to-noise ratio (SNR) is deﬁ  ned as SNR = 
(μ0 – μ1)/(σ0 + σ1). The t-test statistic is the 
same as the SNR except that the denominator is 
(σ0
2 + σ1
2)
1/2. Since (σ0 + σ1) > (σ0
2 + σ1
2)
1/2 SNR 
is a more conservative criterion than the t-test. 
The SNR statistic is preferred over the t-test in 
situations when the sample size in a class is small 
(less than 30) because it does not assume a Gaussian 
distribution for the underlying variables; an assump-
tion which is implicit in the t-test. When combined 
with a permutation test for measuring p-values, the 
SNR statistic is a powerful and widely used tech-
nique for feature selection and class discrimination 
(e.g. Golub et al. 1999; Ramaswamy et al. 2001; 
Shipp et al. 2002; Sun et al. 2004; Goh and Kasabov 
2005; Monti et al. 2005) and is implemented in 
several software packages (e.g. GenePattern and 
Gene Set Enrichment Analysis (GSEA), http://
www.broad.mit.edu/tools/software.html). 
The signal-to-noise (SNR) was computed for 
each gene for each of the 20 imputed datasets and 
for each of the 60 leave-one-out sample perturba-
tion experiments for the core samples. The selected 
genes were those whose p-value for the SNR was 
below 0.01 and the signiﬁ  cance of the SNR for false 
discovery rate (FDR) (Benjamini and Hochberg, 
1995) was above 0.95 in each experiment. 
This procedure identiﬁ  ed 391 robust uni-gene 
markers (given in Supplementary Table 3) for the 
ﬁ  ve core clusters. They consisted of overlapping sets 
of genes, 238 for Luminal A, 234 for Basal, 66 genes 
for Luminal B, 35 genes for ERBB2+ and 118 genes 
for Normals. These included many genes identiﬁ  ed 
in previous studies (Perou et al. 2000; Sorlie et al. 
2003; Loi et al. 2005). For example, the Luminal 
A set included the known estrogen pathway genes 
(ESR1, LIV1, GATA-3) and the Basal set the known 
genes CCNE1, LAD1, and KRT5.
We further reduced this pool to 148 genes using 
the more stringent criteria which used the signiﬁ  -
cance of the SNR for several metrics: the false 
discovery rate, the Q value (Storey and Tibshirani, 
2003), FWER (Dudoit et al. 2002), Bonferroni
correction (Bonferroni, 1935). More details about 
the multiple testing metrics we used are given in 
Supplementary Information I. These 148 genes 
included 79 genes for Luminal A and 60 for Basal 
with an overlap of 31 genes. The other phenotypes Cancer Informatics Online 2006: 2 254
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Table 2a. Collection of uni-gene markers for the Luminal A phenotype. The markers are sorted in decreasing 
order with respect to to the signal-to-noise ratio.
G
r
o
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p
G
e
n
e
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n
d
e
x
Gene Description 
G
e
n
e
B
a
n
k
 
A
c
c
S
N
R
F
D
R
0 0 . 0 6 4 . 1   4 7 4 2 7 H   3   n i e t o r p   g n i d n i b   A T A G   3 A T A G 7 3 4
0 0 . 0 8 3 . 1   8 2 1 7 6 T   ) e s a r e f s n a r t l y t e c a - N   e n i m a l y r a (   1   e s a r e f s n a r t l y t e c a - N   1 T A N 1 3 4
0 0 . 0 8 3 . 1   2 0 7 1 9 2 A A   1   r o t p e c e r   n e g o r t s e   1 R S E 8 3 4
0 0 . 0 7 3 . 1   5 1 3 9 2 H   d e t a l u g e r   n e g o r t s e   , n i e t o r p   1 - V I L   1 - V I L 2 3 4
0 0 . 0 1 2 . 1   8 0 6 4 5 N   0 8 2 1 1 J L F   n i e t o r p   l a c i t e h t o p y h * *   0 8 2 1 1 J L F 0 2 4
0 0 . 0 7 1 . 1   9 6 9 1 5 4 A A   1   e k i l - ) I I S (   A   r o t c a f   n o i t a g n o l e   n o i t p i r c s n a r t   1 L A E C T 6 1 4
0 0 . 0 9 0 . 1   9 3 6 4 7 T   a h p l a   , 3   r o t c a f   r a e l c u n   e t y c o t a p e h   A 3 F N H 4 3 4
436
FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability 
factor receptor) 
AA058828 1.04 0.00
421  Homo sapiens mRNA; cDNA DKFZp313L231 (from clone DKFZp313L231)  AA029948  0.95 0.00
0 0 . 0 5 9 . 0   7 2 4 9 9 6 A A   1   e s a t a h p s o h p s i b - 6 , 1 - e s o t c u r f   1 P B F 4 4 4
0 0 . 0 1 9 . 0   7 2 3 4 0 5 A A   2   r e b m e m   , A V I   e p y t   e s a t a h p s o h p   e n i s o r y t   n i e t o r p   2 A 4 P T P 0 4 4
439 RAB5EP rabaptin-5  AA428477 0.90 0.00
0 0 . 0 7 8 . 0   0 4 7 4 5 4 A A   n i e t o r p   9 3 2 0 A A I K   9 3 2 0 A A I K 5 5 4
0 0 . 0 3 8 . 0   7 6 3 7 2 4 A A   ) n i e t o r p   g n i t c a r e t n i   2 L C B   e k i l - n i s o y m   , l i o c - d e l i o c (   1   n i l c e b   1 N C E B 8 7 3
0 0 . 0 1 8 . 0   3 1 6 2 7 T   n i e t o r p   5 2 0 1 A A I K   5 2 0 1 A A I K 8 4 4
0 0 . 0 1 8 . 0   9 1 6 3 2 R   1 7 1 7 2 C G M   n i e t o r p   l a c i t e h t o p y h   1 7 1 7 2 C G M 5 4 4
0 0 . 0 0 8 . 0   8 2 1 0 9 W   1   n i e t o r p   g n i d n i b   x o b - X   1 P B X 5 3 4
0 0 . 0 9 7 . 0   4 9 8 4 2 R   e v i t i s n e s   n i c y m o r u p   e s a d i t p e p o n i m a   S P P E P N 3 5 4
0 0 . 0 9 7 . 0   0 8 1 5 9 N   n i e t o r p   1 2 0 D A * *   3 1 3 1 5 C O L 5 2 4
454 HIS1 HMBA-inducible  N21081 0.78 0.00
0 0 . 0 8 7 . 0   4 1 9 7 8 4 A A   4   e s a n e g o r d y h e d   ) a t e b - 7 1 (   d i o r e t s y x o r d y h   4 B 7 1 D S H 6 4 4
495 CYB5 cytochrome b-5  R91950 0.78 0.00
0 0 . 0 8 7 . 0   7 6 4 5 4 N   0 8 9 0 1 J L F   n i e t o r p   l a c i t e h t o p y h   0 8 9 0 1 J L F 9 2 4
442 CEGP1 CEGP1 protein  W74079 0.77 0.00
0 0 . 0 6 7 . 0   2 9 7 5 9 H   n i a h c   d e h c n a r b / t r o h s   , e s a n e g o r d y h e d   A   e m y z n e o C - l y c a   B S D A C A 3 4 4
0 0 . 0 6 7 . 0   1 0 0 3 6 N   ) 3 3 0 E 4 3 4 p Z F K D   e n o l c   m o r f (   3 3 0 E 4 3 4 p Z F K D   A N D c   ; A N R m   s n e i p a s   o m o H   6 2 4
0 0 . 0 5 7 . 0   4 7 4 3 7 W   2   e s a r e f s n a r t - S   e n o i h t a t u l g   l a m o s o r c i m   2 T S G M 1 9 4
0 0 . 0 4 7 . 0   8 9 4 3 6 4 A A   1   n i e t o r p   g n i d n i b   ) A 9 7 D C (   n i l u b o l g o n u m m i   1 P B G I 0 8 3
0 0 . 0 3 7 . 0   4 0 0 3 3 R   m o d y l o p   e s u o m   f o   g o l o h t r o   y l e k i l   M O D Y L O P 8 1 4
0 0 . 0 3 7 . 0   8 5 5 3 1 R   e l u c e l o m   n o i s e h d a   l l e c   e t y c o k u e l   d e t a v i t c a   M A C L A 6 9 4
0 0 . 0 1 7 . 0   5 5 1 4 6 6 A A   1   ) e s a d i m a r e c   d i c a (   e s a l o r d y h o d i m a   e n i s o g n i h p s l y c a - N   1 H A S A 4 1 4
0 0 . 0 1 7 . 0   6 7 2 2 7 N   1   r o t c a f   g n i d n i b   A N D   r o t p e c e r   d i o c i t r o c o c u l g   1 F L R G 9 9 3
402 BF B-factor, properdin  H80257 0.70 0.00
0 0 . 0 9 6 . 0   5 7 1 7 1 0 A A   1   e s a n e g o r d y h e d   e t a m a t u l g   1 D U L G 9 3
0 0 . 0 9 6 . 0   1 2 7 1 3 4 A A   n i e t o r p   6 7 8 0 A A I K   6 7 8 0 A A I K 8 2 4
0 0 . 0 9 6 . 0   1 0 4 7 2 4 A A   0 3 7 1 1 J L F   n i e t o r p   l a c i t e h t o p y h   0 3 7 1 1 J L F 8 9 3
493 D5S346 DNA segment, single copy probe LNS-CAI/LNS-CAII (deleted in polyposis)  H99681  0.68 0.00
0 0 . 0 7 6 . 0   1 0 0 2 5 H   5   e s a n e g y x o o n o m   g n i n i a t n o c   n i v a l f   5 O M F 3 0 4
0 0 . 0 7 6 . 0   4 6 5 8 1 4 A A   4 0 7 3 0 0 2 U R E T U   e n o l c   , s i f   1 0 9 0 4 J L F   A N D c   s n e i p a s   o m o H   1 1 4
0 0 . 0 7 6 . 0   7 3 7 7 5 0 A A   ) a l i h p o s o r D   , g o l o m o h   ) 1 p s ( E (   3   t i l p s   f o   r e c n a h n e   e k i l - n i c u d s n a r t   3 E L T 0 3 4
0 0 . 0 6 6 . 0   1 3 1 4 7 N   s d c   e t e l p m o c   , A N R m   , 6 6 5 6 9 6 4 : E G A M I   8 8 5 2 2 : C G M   e n o l c   , s n e i p a s   o m o H   3 3 4
0 0 . 0 5 6 . 0   6 0 4 4 6 6 A A   B 4   t n e n o p m o c   t n e m e l p m o c   B 4 C 4 9 4
0 0 . 0 5 6 . 0   8 9 1 8 3 R   e s a t c u d e r   e n i d i r e t p o r d y h i d   d i o n i u q   R P D Q 1 7 3
0 0 . 0 5 6 . 0 -   8 4 0 0 6 T   c i r e t n e   , e l c s u m   h t o o m s   , 2   a m m a g   , n i t c a   2 G T C A 2 6 2
256  ESTs  AA074677 -0.66 0.00
0 0 . 0 8 6 . 0 -   8 9 7 0 2 N   g o l o m o h   e n e g o c n o   l a r i v   a m o c r a s   e n i l e f   4   n a m r e k c u Z - y d r a H   t i k - v   T I K 9 6
0 0 . 0 8 6 . 0 -   5 8 0 6 8 4 A A   0 1   a t e b   , n i s o m y h t   0 1 B S M T 1 1 2
0 0 . 0 9 6 . 0 -   8 4 7 0 8 H   7 9 6 0 1 J L F   n i e t o r p   l a c i t e h t o p y h   7 9 6 0 1 J L F 8 3 2
0 0 . 0 0 7 . 0 -   2 9 1 6 2 0 A A   ) e s a n i e t o r p o k u e l i t n a (   r o t i b i h n i   e s a e t o r p   e t y c o k u e l   y r o t e r c e s   I P L S 3 4 2
0 0 . 0 0 7 . 0 -   2 4 6 3 3 R   i p   e s a r e f s n a r t - S   e n o i h t a t u l g   1 P T S G 0 8 1
254
 Homo sapiens cDNA FLJ11796 fis, clone HEMBA1006158, highly similar to Homo sapiens 
transcription factor forkhead-like 7 (FKHL7) gene 
N22552 -0.71 0.00
186 NRG1 neuregulin 1  R72075 -0.72 0.00
0 0 . 0 3 7 . 0 -   9 0 1 0 9 N   8 7 6 2 2 J L F   n i e t o r p   l a c i t e h t o p y h * *   8 7 6 2 2 J L F 1 6 2
244 TONDU TONDU  AA700322 -0.74 0.00
0 0 . 0 6 7 . 0 -   6 7 7 8 7 R   K   , e p y t   r o t p e c e r   , e s a t a h p s o h p   e n i s o r y t   n i e t o r p   K R P T P 2 3 2
0 0 . 0 6 7 . 0 -   5 8 4 5 5 0 A A   9 2   g n i n i a t n o c - f i t o m   e t i t r a p i r t   9 2 M I R T 8 4 2
0 0 . 0 7 7 . 0 -   9 8 7 3 5 4 A A   7   e s a n i k   e n i s o r y t   n i e t o r p   7 K T P * *   7 K T P 5 8 1
0 0 . 0 7 7 . 0 -   2 0 7 4 5 4 A A   1   n i e t o r p   g n i d n i b   d i c a   c i o n i t e r   r a l u l l e c   1 P B A R C 7 7 1
241 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)  W42723  -0.77 0.00
0 0 . 0 7 7 . 0 -   0 2 1 3 9 W   2 0 3 3 0 0 3 P R 2 T N   e n o l c   , s i f   1 6 7 4 1 J L F   A N D c   s n e i p a s   o m o H   0 4 2
0 0 . 0 7 7 . 0 -   6 5 0 4 6 6 A A   e s a d i t p e p o d n e   l y l o r p   P E R P 7 8 1
0 0 . 0 8 7 . 0 -   8 2 0 4 6 4 A A   5 2 5 4 1 J L F   n i e t o r p   l a c i t e h t o p y h   5 2 5 4 1 J L F 7 5 2
0 0 . 0 1 8 . 0 -   1 6 7 9 7 N   2   n i e t o r p   g n i t c a r e t n i - t i n u b u s   c i t y l a t a c   e s a n i k   n i e t o r p   t n e d n e p e d - A N D   2 P I K 4 3 2
0 0 . 0 2 8 . 0 -   6 9 4 2 5 N   3   r e b m e m   , y l i m a f   G T B   3 G T B 9 9 1
0 0 . 0 2 8 . 0 -   1 4 3 3 5 4 A A   n i e t o r p   x i l e h - p o o l - x i l e h   e v i t a g e n   t n a n i m o d   , 4   g n i d n i b   A N D   f o   r o t i b i h n i   4 D I 7 9
0 0 . 0 4 8 . 0 -   5 2 2 1 0 1 A A   i p   , r o t p e c e r   A   ) A B A G (   d i c a   c i r y t u b o n i m a - a m m a g   P R B A G 5 4 2
259 SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), member 6  AA186605  -0.84 0.00
0 0 . 0 5 8 . 0 -   0 0 3 5 5 4 A A   A   n i e t o r p   n i a m o d   k c o h s   d l o c   A D S C 8 6
0 0 . 0 6 8 . 0 -   7 1 2 5 2 4 A A   ) l a t n e c a l p (   n i r e h d a c - P   , 1   e p y t   , 3   n i r e h d a c   3 H D C 2 4 2
258 B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5  AA043551  -0.86 0.00
222 LAD1 ladinin 1  T97710 -0.87 0.00
0 0 . 0 7 8 . 0 -   7 8 4 8 5 N   n i e t o r p   1 9 6 1 A A I K   1 9 6 1 A A I K 3 1 2
0 0 . 0 8 8 . 0 -   3 1 2 4 3 0 A A   3   n i e t o r p   e n a r b m e m   l a r g e t n i   3 M T I 6 9
0 0 . 0 0 9 . 0 -   5 7 1 9 9 5 A A   1   n i e t o r p   g n i d n i b   t n e m e l e   e v i t i s n e s   e s a e l c u n   1 P E S N 4 0 2
0 0 . 0 3 9 . 0 -   3 5 7 4 5 0 A A   n i e t o r p   8   r o t c a f   F G E - e l u b o l g   t a f   k l i m   8 E G F M 0 5 2
183
PLOD procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos 
syndrome type VI) 
AA476240 -0.96 0.00
0 0 . 0 8 0 . 1 -   1 4 9 8 4 4 A A   5   g n i n i a t n o c   n i a m o d   C H H D   , r e g n i f   c n i z * *   5 C H H D Z 1 5 2
0 0 . 0 0 1 . 1 -   9 6 4 7 1 R   2 4 4 2 1 J L F   n i e t o r p   l a c i t e h t o p y h   2 4 4 2 1 J L F 0 1 2
0 0 . 0 8 1 . 1 -   9 3 1 6 6 R   1   d n a g i l   ) f i t o m   C - 3 X - C (   e n i k o m e h c   1 L C 3 X C 2 5 2
C
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Table 2b. Collection of uni-gene markers for the Luminal B phenotype. The markers are sorted in
decreasing order with respect to to the signal-to-noise ratio.
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G
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n
e
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c
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192 SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp)  T70043  1.14 0.00
0 0 . 0 0 1 . 1   7 9 8 6 4 T   1   e l u c e l o m   g n i t a l u g e r   n o i s e h d a   1 M R D A 8 3 1
0 0 . 0 7 0 . 1   8 1 1 1 0 R   e s a d i x o p e   e n e l a u q s   E L Q S 9 1 2
205 GGH gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase)  AA455800  1.03 0.00
0 0 . 0 8 8 . 0   4 1 2 0 0 6 A A   r e t r o p s n a r t   e n a r b m e m   l a r g e t n i   e v i t a t u p   7 2 C L 6 0 2
0 0 . 0 4 8 . 0   1 0 8 9 4 T   7 7 4 2 C G M   n i e t o r p   l a c i t e h t o p y h   7 7 4 2 C G M 7 3 1
195 MDS029 uncharacterized hematopoietic stem/progenitor cells protein MDS029  AA431199  0.82 0.00
0 0 . 0 0 8 . 0   0 2 6 2 6 N   1   r e b m e m   , K   y l i m a f b u s   , l e n n a h c   m u i s s a t o p   1 K N C K 0 8 2
426  Homo sapiens mRNA; cDNA DKFZp434E033 (from clone DKFZp434E033)  N63001  -0.82 0.00
0 0 . 0 3 8 . 0 -   9 7 0 4 7 W   n i e t o r p   1 P G E C   1 P G E C 2 4 4
0 0 . 0 3 8 . 0 -   2 5 1 1 7 T   8 4 9 0 1 J L F   n i e t o r p   l a c i t e h t o p y h   8 4 9 0 1 J L F 7 7 4
0 0 . 0 8 8 . 0 -   0 4 7 5 9 R   3   e s a n o x o a r a p   3 N O P 1 5 3
0 0 . 0 8 8 . 0 -   4 3 5 7 7 6 A A   2   a m m a g   , n i n i m a l   2 C M A L 6 6 2
0 0 . 0 9 8 . 0 -   9 0 3 6 6 R   e s a n e g y x o o n o m   g n i t a d i m a - a h p l a   e n i c y l g l y d i t p e p   M A P 4 2 3
0 0 . 0 3 9 . 0 -   8 3 7 9 8 N   0 9 5 3 1 0 2 Y M A R B   e n o l c   , s i f   4 8 2 7 3 J L F   A N D c   s n e i p a s   o m o H   2 3 3
C
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e
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Table 2c. Collection of uni-gene markers for the ERBB2+ phenotype. The markers are sorted in 
decreasing order with respect to to the signal-to-noise ratio.
G
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7
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
AA480116 2.27 0.00
9
**Homo sapiens mRNA; cDNA DKFZp761B0319 (from clone 
DKFZp761B0319)
AA504615 1.84 0.00
0 0 . 0 8 5 . 1   1 0 0 8 4 4 A A   1   e k i l - P B T   1 L P B T 0 1
5 TRAP100 thyroid hormone receptor-associated protein (100 kDa)  N54470  1.43 0.00
0 0 . 0 9 3 . 1   7 8 4 8 5 N   n i e t o r p   1 9 6 1 A A I K   1 9 6 1 A A I K 3 1 2
0 0 . 0 1 2 . 1   2 0 7 3 5 H   7   n i e t o r p   d n u o b - r o t p e c e r   r o t c a f   h t w o r g   7 B R G 8
235 KIAA1971 **similar to junction-mediating and regulatory protein p300 JMY  N71692  1.12 0.00
0 0 . 0 8 0 . 1   2 3 7 7 3 0 A A   e s a d i x o   l y s y l   X O L 4 0 3
0 0 . 0 2 0 . 1   3 5 6 8 9 5 A A   ) e k i l - I   n i l c i c s a f (   2   r o t c a f   c i f i c e p s   t s a l b o e t s o   2 - F S O 6 0 3
0 0 . 0 1 0 . 1 -   8 3 2 6 8 4 A A   ) 8 7 2   n i e t o r p   g n i d n i b   n i t c a (   a t e b   , B   n i m a l i f   B N L F 5 8 4
270 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe)  H67202  -1.06 0.00
0 0 . 0 6 0 . 1 -   3 2 2 0 1 0 A A   Q   r e b m e m   , y l i m a f   e n o t s i h   B 2 H   Q F B 2 H 4 0 1
300 CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4  W32509  -1.08 0.00
0 0 . 0 1 1 . 1 -   2 0 9 8 1 R   9 0 5 0 1 J L F   n i e t o r p   l a c i t e h t o p y h   9 0 5 0 1 J L F 1 1 1
C
o
r
e
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Table 2d. Collection of uni-gene markers for the Basal phenotype. The markers are 
sorted in decreasing order with respect to to the signal-to-noise ratio.
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n
e
 
i
n
d
e
x
Gene Description 
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n
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R
258 B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5  AA043551 1.10 0.00
254
 Homo sapiens cDNA FLJ11796 fis, clone HEMBA1006158, highly similar to Homo 
sapiens transcription factor forkhead-like 7 (FKHL7)g ene
N22552 1.07 0.00
256  ESTs  AA074677 1.03 0.00
183
PLOD procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-
Danlos syndrome type VI)
AA476240 0.92 0.00
257 FLJ14525 hypothetical protein FLJ14525  AA464028 0.85 0.00
255 CHI3L2 chitinase 3-like 2  AA668821 0.85 0.00
175 SIAT4C sialyltransferase 4C (beta-galactosidase alpha-2,3-sialytransferase) AA453813 0.84 0.00
215 CCNE1 cyclin E1  T54121 0.84 0.00
172 STK38 serine/threonine kinase 38  AA521346 0.84 0.00
199 BTG3 BTG family, member 3  N52496 0.84 0.00
273 DGUOK deoxyguanosine kinase  R07506 0.83 0.00
228 TP53BP2 tumor protein p53 bindingp rotein, 2  H69077 0.81 0.00
204 NSEP1 nuclease sensitive element bindingp rotein 1  AA599175 0.79 0.00
238 FLJ10697 hypothetical protein FLJ10697  H80748 0.76 0.00
272 PRAME preferentially expressed antigen in melanoma  AA598817 0.76 0.00
243 SLPI secretory leukocyte protease inhibitor (antileukoproteinase) AA026192 0.75 0.00
268 CP ceruloplasmin (ferroxidase) H86554 0.75 0.00
259 SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), member 6  AA186605  0.72 0.00
231 CDK2AP1 CDK2-associated protein 1  R78607 0.72 0.00
224 MAFG v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) AA045436 0.71 0.00
269 RCL putative c-Myc-responsive AA132086 0.70 0.00
226 TMSNB thymosin, beta, identified in neuroblastoma cells  N91887 0.70 0.00
217 LANP-L lecuine-rich acidic protein-like protein AA130595 0.70 0.00
245 GABRP gamma-aminobutyric acid (GABA) A receptor, pi AA101225 0.69 0.00
233 S100A11 S100 calcium bindingp rotein A11 (calgizzarin) AA464731 0.68 0.00
185 PTK7 **PTK7 protein tyrosine kinase 7  AA453789 0.68 0.00
173 DKFZP434L0718 hypothetical protein DKFZp434L0718 AA437140 0.67 0.00
239  Homo sapiens cDNA FLJ31360 fis, clone MESAN2000572  AA031989 0.67 0.00
222 LAD1 ladinin 1  T97710 0.66 0.00
506 CRAT carnitine acetyltransferase AA621218 -0.65 0.00
394 RGS5 regulator of G-protein signalling 5  AA668470 -0.66 0.00
428 KIAA0876 KIAA0876 protein AA431721 -0.66 0.00
431 NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) T67128 -0.66 0.00
443 ACADSB acyl-Coenzyme A dehydrogenase, short/branched chain  H95792 -0.67 0.00
458 FMOD fibromodulin  AA485748 -0.68 0.00
442 CEGP1 CEGP1 protein W74079 -0.70 0.00
454 HIS1 HMBA-inducible  N21081 -0.70 0.00
498  ESTs  N73949 -0.70 0.00
488 ECE1 endothelin converting enzyme 1  H18427 -0.71 0.00
457 RNASE4 ribonuclease, RNase A family, 4  T60163 -0.71 0.00
452 PLAT plasminogen activator, tissue  AA447797 -0.73 0.00
421  Homo sapiens mRNA; cDNA DKFZp313L231 (from clone DKFZp313L231) AA029948 -0.76 0.00
346 HRASLS3 HRAS-like suppressor 3  AA476438 -0.77 0.00
425 LOC51313 **AD021 protein N95180 -0.78 0.00
501 MRPS14 **mitochondrial ribosomal protein S14  T51290 -0.79 0.00
387 PRO1489 hypothetical protein PRO1489  AA131299 -0.80 0.00
500
SLC11A3 solute carrier family 11 (proton-coupled divalent metal ion transporters), 
member 3 
AA056733 -0.80 0.00
495 CYB5 cytochrome b-5  R91950 -0.82 0.00
429 FLJ10980 hypothetical protein FLJ10980  N45467 -0.83 0.00
444 FBP1 fructose-1,6-bisphosphatase 1  AA699427 -0.83 0.00
440 PTP4A2 protein tyrosine phosphatase type IVA, member 2  AA504327 -0.85 0.00
439 RAB5EP rabaptin-5 AA428477 -0.88 0.00
436
FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular 
permeability factor receptor)
AA058828 -0.91 0.00
502
DKFZp586H0623 putative UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase T9 
T51229 -0.94 0.00
447
 **Homo sapiens cDNA FLJ11796 fis, clone HEMBA1006158, highly similar to Homo 
sapiens transcription factor forkhead-like 7 (FKHL7)g ene
AA495790 -1.11 0.00
445 MGC27171 hypothetical protein MGC27171  R23619 -1.14 0.00
434 HNF3A hepatocyte nuclear factor 3, alpha T74639 -1.18 0.00
435 XBP1 X-box bindingp rotein 1  W90128 -1.20 0.00
437 GATA3 GATA bindingp rotein 3  H72474 -1.27 0.00
433  Homo sapiens, clone MGC:22588 IMAGE:4696566, mRNA, complete cds  N74131 -1.46 0.00
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(Luminal B, ERBB2+ and Normal) had far fewer 
gene markers (15 for Luminal B, 14 for ERBB2+ 
and 20 for Normal core clusters). These genes are 
listed in Tables 2 a–d and those also identiﬁ  ed in 
Sorlie et al. (2003) are marked with a*. A heat 
map of the core clusters using these 148 genes is 
shown in Figure 2. 
Patterns (Multi-gene Markers)
for the Core Clusters 
The complexity of BCA makes it unlikely that single 
genes can predict phenotype. Instead, one expects 
combinations of genes to be better at identifying 
phenotype. Consequently, we used “ patterns” (as 
deﬁ  ned in Crama et al. 1988; Alexe and Hammer, 
2005; Bhanot et al. 2005) to distinguish the core 
clusters. A pattern is a set of linear constraints on 
the expression levels of a group of genes satisﬁ  ed 
by many samples in a particular cluster and by few 
samples in other clusters. For example, the pattern PA 
below is satisﬁ  ed by all samples in the “Luminal A” 
cluster and by none of the non-Luminal A samples:
PA = [Expression of GATA3 ≥ 0.49 ].AND.
          [Expression of Liv-1 ≥ – 0.25]
For illustration, Figure 3 shows two patterns PA 
and NA, in the 2-d expression plane for GATA3 
and Liv-1. 
A pattern is characterized by its degree, preva-
lence, and homogeneity. The degree is the number 
of genes appearing in its deﬁ  ning conditions. The 
prevalence of a pattern is the percent of positive 
(negative) cases which satisfy the pattern. The 
homogeneity of a pattern is the percentage of 
positive (negative) cases covered by it. In general, 
patterns useful for classiﬁ  cation have low degree 
and high prevalence and homogeneity. 
We identified all patterns for the 60 core 
samples over the selected 148 genes by applying 
the combinatorial algorithm described in (Alexe 
and Hammer, 2005). Brieﬂ  y, each sample from a 
core cluster was placed in a box by deﬁ  ning cuts 
in gene expression space which distinguish it from 
the samples belonging to other core clusters. The 
boxes were then merged by extending them along 
Table 2e. Collection of uni-gene markers for the Normal phenotype. The markers are sorted in decreasing 
order with respect to to the signal-to-noise ratio.
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Figure 2. Heatmap of 148 uni-genes for the samples in core categories.Cancer Informatics Online 2006: 2 259
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Figure 3. An example of a pattern (pattern PA) characteristic of the Luminal A core cluster (Cluster A)  and an example of a pattern (pattern 
NA ) characteristic of the non-Luminal A cases. Notice that P is satisﬁ  ed by all the samples in the Luminal A group, while N is satisﬁ  ed by 88% 
of the non-Luminal A cases. Both patterns P and N are expressed as bounding constraints on the expressions of genes Liv-1 and Gata-3.
all possible dimensions without allowing any 
member of the opposite class to be included in 
the box. The maximal boxes so obtained deﬁ  ned 
the patterns.
The pattern parameters (degree, prevalence, and 
homogeneity) were determined by estimating the 
classiﬁ  cation accuracy of a weighted-voting model 
constructed on pattern data through 10-  fold cross-
validation experiments. Pattern-based weighted 
voting is a meta-classiﬁ  cation scheme in which 
individual patterns are “voters” for a phenotype. 
The performance of a multi-pattern meta-clas-
siﬁ  cation system is better than the performance 
of single patterns if the patterns are uncorrelated 
(Merz, 1998). Uncorrelated patterns were selected 
by requiring the patterns to be deﬁ  ned on non-over-
lapping subsets of features. To avoid over-ﬁ  tting, 
the patterns were required to use no more than ﬁ  ve 
genes each. 
We found many patterns of degree 2 and 3 
for each phenotype, each of which was common 
to more than 90% of the samples in the cores. 
Table 3 presents some of these patterns. The 
striking feature of Table 3 is that simple conditions 
on a few genes are able to generate a very clean 
classiﬁ  cation in the cores. Several genes occurred 
frequently in the patterns, suggesting an active 
association with disease. For example, KIAA1691, 
PREP, CX3CL1, LIV-1, PLOD, GATA-3 occur in 
20% of patterns for Luminal A, while PRAME, 
PLAT, CCNE1, FKHL7, clone MGC:22588 
IMAGE:4696566, occur in 15% of the patterns 
for the Basal group. There are also several genes 
which are good uni-gene markers but are not found 
in patterns.
Consistency of Core Assignments 
Using Either Patterns or Clustering 
A positive pattern is a set of conditions satisﬁ  ed 
by a sample that belongs to a core cluster. A nega-
tive pattern is a set of conditions satisﬁ  ed by a 
sample that belongs to the complement of the core 
cluster. For each unlabeled sample we counted the 
number of positive minus the number of negative 
patterns satisﬁ  ed by it for each core cluster. The 
sample was assigned to the core cluster for which 
the ratio obtained by dividing this number to the 
total number of patterns for the core cluster, was 
positive and maximum. If the maximum ratio was 
negative or if it was assigned to multiple core clus-
ters then the sample remained unclassiﬁ  ed (Alexe 
et al. 2005c). The classiﬁ  cation of samples to cores 
was validated using leave-one-out experiments on 
patterns. Over the sixty samples in the cores, in 
each such experiment, the entire procedure (gene 
selection, pattern extraction and sample classiﬁ  -
cation) was repeated sixty times, once for each 
omitted sample.
A comparison of our clustering and pattern 
assignments with the original classification is 
presented in Table 4. The color scheme is that if 
the sample is robustly assigned to a phenotype, 
its entry is the color of that phenotype. Samples 
whose classiﬁ  cation is either poor or ambiguous 
are in black or left blank respectively. When the Cancer Informatics Online 2006: 2 260
Bhanot et al
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Table 4. Phenotype classiﬁ  cation of breast cancer based on core 
clusters and pattern scores.Cancer Informatics Online 2006: 2 263
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Table 5. Phenotype prediction for previously unassigned breast cancer samples. Cancer Informatics Online 2006: 2 264
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Table 6. Classiﬁ  cation accuracy of pattern models through leave-one-out 
cross validation experiments.
pattern and cluster classiﬁ  ers agree, the assignment 
can be considered accurate. When they differ, no 
classiﬁ  cation is possible. From a treatment perspec-
tive, the recommendation of such an inconclusive 
assignment would be retesting. The clustering and 
patterns classiﬁ  ers for the unassigned samples in 
the Sorlie et al. paper are shown in Table 5. Some 
of these originally unassigned samples are assigned 
to a consistent phenotype by our methods. 
Table 6 summarizes the sensitivity and speci-
ﬁ  city of the pattern based classiﬁ  er showing once 
again the robustness of the classification into 
phenotypes Normal, Luminal A and Basal and 
the unreliability of the other two phenotype clas-
siﬁ  cations.
Validation on an External Dataset 
Data 2
We used the markers identiﬁ  ed in Data 1 to clas-
sify samples in Data 2. These two datasets had 93 
genes in common. Of these, 79 were in our 391 
uni-gene set and a subset of 38 of these were in 
the smaller subset of 148 genes. Of the latter, 23 
were markers for Luminal A, 4 were markers for 
Luminal B, 3 were markers for ERBB2+ and 12 
were markers for the Basal group. For each of the 
38 genes, we normalized the data sets relative to 
each other by equating the average intensity of 
each gene for the normal samples in the two data 
sets. In each dataset, the expression level of each 
gene was replaced with its quartile value across all 
samples. We recomputed a pattern-based classiﬁ  er 
trained on the known core clusters in the Sorlie 
et al. (2003) data and used it to predict the pheno-
type for Ma et al. 2003 samples. 
Figure 4 shows a heat map of the 38 genes in 
common between the datasets. This plot includes 
all core samples from Data 1 and all samples 
from Data 2. The Normal samples from both sets 
cluster nicely showing that the global normaliza-
tion was done correctly. The Luminal A cluster 
is easily identiﬁ  ed because all Luminal A core 
samples from Data 1 cluster together with several 
samples from Data 2. There is also a distinct Basal 
cluster with most Data 1 Basal samples and a few 
Data 2 samples on its edges. Finally, there is 
another cluster with some Core B samples which 
looks quite similar to Luminal A. The core C 
samples are mixed in with the Basal cluster (as was 
already noticed in Figure 1c). We conclude that it 
is not possible to assign Luminal B or ERBB2+ 
phenotypes to samples in Data 2 based on Data 
1 because a) There are very few genes in these 
categories (3/38 for ERBB2+ and 4/38 for Luminal 
B), b) the ERBB2 gene is missing in Data 2 and 
c) The quality of the patterns using the 38 genes 
for these two phenotypes is poor. Indeed, for core 
C, there are no patterns at all and for core B, the 
patterns are of poor statistical quality.
To further validate the consistency of our 
assignments, we trained a pattern-based classiﬁ  ca-
tion model on quartile discretized Data 1 samples 
and used it to predict the phenotype for the samples 
in Data 2 using majority voting. When the predic-
tion from patterns agreed with the prediction from 
clustering as in Figure 4, we felt conﬁ  dent of the 
diagnosis, otherwise not. Our predicted phenotypes 
for the Ma et al. data are given in Table 7. 
Pathways for each Core 
To identify processes/pathways that are common 
and particular to the different phenotypes, we 
used the bioinformatics public resources DAVID 
(Dennis et al. 2003), BioRag (Pandey et al. 2004), Cancer Informatics Online 2006: 2 265
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Table 7. Predicted phenotype for samples in Ma et al. data using patterns 
from core clusters in Sorlie et al. 2003. We are conﬁ  dent of the pheno-
type assignment for those samples marked in color in columns 9 and 10. Cancer Informatics Online 2006: 2 266
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d e t a l e r   r e c n a c   t s a e r B s r o t p e c e R _ r a e l c u N   2 0 7 1 9 2 A A   1   r o t p e c e r   n e g o r t s e   1 R S E
KIT v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene 
homolog
N20798  Regulation of BAD phosphorylation
Breast cancer related, Loss of c-kit expression 
has been reported in 80-90% of breast cancer 
specimens, suggesting a possible role in the 
development of tumors. Introduction of the c-kit 
gene leads to growth suppression of a breast 
cancer cell line, MCF-7 (Nishida et al., 1996)
NRG1 neuregulin 1  R72075 
Neuroregulin receptor degredation protein-1 Controls 
ErbB3 receptor recycling
Breast cancer related, direct ligand for ERBB3 
and ERBB4. Indirect activator of ERBB2.
NSEP1 nuclease sensitive 
element binding protein 1 
AA599175  D4-GDI Signaling Pathway
Breast cancer related. Target of Akt 
phosphorylation. Disruption inhibits tumor growth 
(Sutherland et al., 2005)
ID4 inhibitor of DNA binding 4, 
dominant negative helix-loop-helix 
protein
AA453341 TGF-beta  signaling  pathway
Cancer related. May contribute to rat mammary 
gland carcinogenesis by inhibiting mammary 
epithelial cell differentiation and stimulating 
mammary epithelial cell growth (Shan et al., 
2003). Down-regulated in gastric adenocarcinoma 
and leukemia.
GSTP1 glutathione S-transferase 
pi
R33642
Multi-Drug Resistance Factors,Glutathione 
metabolism
Cancer related. Lost in prostate cancer, lung 
cancer and squamous cell carcinoma.
 TFF3. Homo sapiens, clone 
MGC:22588 IMAGE:4696566, 
mRNA, complete cds 
N74131  Trefoil Factors Initiate  Mucosal Healing
Cancer related. TFF3, activates STAT3 
(oncogene) signaling in human colonic cancers 
(Rivat et al., 2005).
FLT1 fms-related tyrosine kinase 
1 (vascular endothelial growth 
factor/vascular permeability factor 
receptor)
AA058828  VEGF, Hypoxia, and Angiogenesis Cancer related, angiogenesis.
SLPI secretory leukocyte protease 
inhibitor (antileukoproteinase) 
AA026192
Proepithelin Conversion to Epithelin and Wound 
Repair Control
Immune response related.
BF B-factor, properdin  H80257  Complement and coagulation cascades Immune response related.
C4B complement component 4B  AA664406  Complement and coagulation cascades Immune response related.
ASAH1 N-acylsphingosine 
amidohydrolase (acid ceramidase) 
1
AA664155 Glycosphingolipid  metabolism
Anti-apoptotic. Metabolizes ceramide to 
sphingosine-1-phosphate (SPP), an inducer of 
proliferation.
PLOD procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 
(lysine hydroxylase, Ehlers-Danlos 
syndrome type VI) 
g n i l l e d o m   e u s s i t n o i t a d a r g e d   e n i s y L   0 4 2 6 7 4 A A
ACTG2 actin, gamma 2, smooth 
muscle, enteric 
g n i l l e d o m   e u s s i t n o i t c e f n I   -   a r e l o h C   8 4 0 0 6 T
ACADSB acyl-Coenzyme A 
dehydrogenase, short/branched 
chain
H95792 Fatty_Acid_Synthesis,Bile  acid  biosynthesis
FBP1 fructose-1,6-
bisphosphatase 1 
AA699427  Glycolysis / Gluconeogenesis
HSD17B4 hydroxysteroid (17-
beta) dehydrogenase 4 
AA487914
Mechanism of Gene Regulation by Peroxisome 
Proliferators via PPARa(alpha), Androgen and 
estrogen metabolism
MGST2 microsomal glutathione S-
transferase 2 
W73474 Glutathione  metabolism
QDPR quinoid dihydropteridine 
reductase
R38198 Folate  biosynthesis
GLUD1 glutamate dehydrogenase 
1
AA017175 Glutamate  metabolism
GGH gamma-glutamyl hydrolase 
(conjugase,
folylpolygammaglutamyl
hydrolase)
AA455800 Folate  biosynthesis
Cancer related. Identified as a biomarker for 
pulmonary neuroendocrine tumors (he et al., 
2004)
LAMC2 laminin, gamma 2  AA677534  Inflammatory_Response_Pathway
Cancer related. Involved in tumor invasion and 
metastases e.g. in pancreatic ductal 
adenocarcinoma (Takahashi et al., 2002) and 
endometrial adenocarcinomas (Maatta et al., 
2004).
SDHA succinate dehydrogenase 
complex, subunit A, flavoprotein 
(Fp)
T70043 Oxidative  phosphorylation
PON3 paraoxonase 3  R95740  gamma-Hexachlorocyclohexane degradation
core A
core B
Table 8. A complete listing of the associated pathways for the biomarkers available in different databases 
on the web (BIOCARTA, KEGG, GENMAPP).
(continued)Cancer Informatics Online 2006: 2 267
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ERBB2 v-erb-b2 erythroblastic 
leukemia viral oncogene homolog 
2, neuro/glioblastoma derived 
oncogene homolog (avian) 
AA480116  Role of ERBB2 in Signal Transduction and Oncology Breast cancer related
F2R coagulation factor II 
(thrombin) receptor 
AA455910  Thrombin signaling and protease-activated receptors
Breast cancer related, matrix metalloprotease-1 
receptor that promotes invasion and 
tumorigenesis of breast cancer cells (Boire et al, 
2005)
PPARBP PPAR binding protein  T57034  CARM1 and Regulation of the Estrogen Receptor
Breast cancer related, ESR1 coactivator. 
Overexpressed in breast cancer. May play a role 
in mammary epthelial differentiation (Zhu et al., 
1999)
FLNB filamin B, beta (actin 
binding protein 278) 
AA486238 MAPK  signaling  pathway
 CDK6. Homo sapiens cDNA 
FLJ31360 fis, clone 
MESAN2000572
AA031989  Cyclins and Cell Cycle Regulation
Breast cancer related. CDK6 gene, inhibits 
proliferation of human mammary epithelial cells 
(Lucas et al., 2004)
SIAT4C sialyltransferase 4C (beta-
galactosidase alpha-2,3-
sialytransferase)
AA453813
Steps in the Glycosylation of Mammalian N-linked 
Oligosaccarides
Cancer related. Down-regulated in RCC (Saito et 
al., 2002)
 Homo sapiens, clone MGC:22588 
IMAGE:4696566, mRNA, 
complete cds 
N74131  Trefoil Factors Initiate  Mucosal Healing
Cancer related. TFF3, activates STAT3 
(oncogene) signaling in human colonic cancers 
(Rivat et al., 2005).
FLT1 fms-related tyrosine kinase 
1 (vascular endothelial growth 
factor/vascular permeability factor 
receptor)
AA058828  VEGF, Hypoxia, and Angiogenesis Cancer related, angiogenesis.
PLOD procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 
(lysine hydroxylase, Ehlers-Danlos 
syndrome type VI) 
AA476240 Lysine  degradation
Catalyzes the hydroxylation of lysyl residues in 
collagen-like peptides. The resultant hydroxylysyl 
groups are attachment sites for carbohydrates in 
collagen
 **Homo sapiens cDNA FLJ11796 
fis, clone HEMBA1006158, highly 
similar to Homo sapiens 
transcription factor forkhead-like 7 
(FKHL7) gene 
AA495790 Integrin-mediated  cell  adhesion
Cancer related. RHOB protein, tumor suppressor 
and proapoptotic.
SLPI secretory leukocyte protease 
inhibitor (antileukoproteinase) 
AA026192
Proepithelin Conversion to Epithelin and Wound 
Repair Control
Immune response related.
PLAT plasminogen activator, 
tissue
AA447797  Complement and coagulation cascades Tissue remodelling
FMOD fibromodulin  AA485748  Small Leucine-rich Proteoglycan (SLRP) molecules
Affects the rate of fibrils formation. May have a 
primary role in collagen fibrillogenesis
DGUOK deoxyguanosine kinase  R07506  Purine metabolism
ACADSB acyl-Coenzyme A 
dehydrogenase, short/branched 
chain
H95792 Fatty_Acid_Synthesis,Bile  acid  biosynthesis
FBP1 fructose-1,6-
bisphosphatase 1 
AA699427  Glycolysis / Gluconeogenesis
MAFG v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
G (avian) 
AA045436  Oxidative Stress Induced Gene Expression Via Nrf2
CP ceruloplasmin (ferroxidase)  H86554  Porphyrin and chlorophyll metabolism
GSTM1 glutathione S-transferase 
M1
AA290737 Glutathione  metabolism
ACADVL acyl-Coenzyme A 
dehydrogenase, very long chain 
AA464163 Fatty_Acid_Synthesis,Bile  acid  biosynthesis
core E
core C
core D
iHOP (Hoffmann and Valencia, 2004) and BRB 
Tools (http://linus.nci.nih.gov/BRB-ArrayTools.
html). The method used for GO functional class 
scoring is given in Supplementary Information II. 
Table 8 is a detailed explanation of some of 
the 148 uni-gene biomarkers identiﬁ  ed for each 
core (see also Tables 2a – d). Table 9 presents the 
GO categories enriched for the genes associated 
with the cores. The statistical signiﬁ  cance of the 
enriched GO categories is computed as described 
in Supplementary Information II. The complete list 
of gene markers for the core phenotypes involved 
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in the enriched GO categories is available in 
Supplementary Table 4.
Whereas we discuss markers for each core 
subtype, we have strong conﬁ  dence only in the 
markers for Luminal A and Basal.
In Luminal A, ESR1 is up-regulated, indi-
cating that the estrogen receptor pathway is 
turned on. 
The KIT gene was already known to be lost in 
breast cancer. Introduction of the c-kit gene leads to 
growth suppression of a breast cancer cell line, MCF-7 
(Nishida et al. 1996). The Neuregulin 1 gene, which 
is up-regulated, is a direct ligand for ERBB3 and 
ERBB4, and an indirect activator of ERBB2, though 
the ERBB2+ subtype is identiﬁ  ed with Cluster C. The 
nuclease sensitive element binding protein (NSEP1), 
which is also up-regulated, is known to inhibit p53 
induced apoptosis (Zhang et al. 2003). It has also been 
recently shown to be a target of Akt phosphorylation, 
and that disruption of phosphorylation inhibits tumor 
growth (Sutherland et al. 2005). This gene is involved 
in D4-GDI signaling pathway, which may also be 
up-regulated.
A number of Luminal A markers were previ-
ously identiﬁ  ed cancer related genes. The ID4 
gene, which was also reported to be down-regu-
lated in gastric adenocarcinoma and leukemia, 
may cause the alteration of the TGF-beta signaling 
pathway which regulates the growth and prolifera-
tion of cells, blocking the growth of many different 
cell types. The TGF-beta receptor includes 
Type I and Type II subunits that are serine-
threonine kinases that signal through the Smad 
family of proteins. Another cancer related gene is 
GSTP1, which was reported to be lost in different 
types of cancers including prostate cancer, lung 
cancer and squamous cell carcinoma. Other cancer 
related genes include the TFF3 gene, which was 
shown to activate STAT3, (an oncogene) signaling 
in human colonic cancers (Rivat et al. 2005) and 
the VEGF receptor FLT1 gene.
Other Luminal A marker genes include up-regu-
lated immune system related genes (SLPI , BF, 
and C4B), anti-apoptotic gene ASAH1; collagen 
related gene PLOD and actin gamma 2 gene. Other 
genes constitute mostly metabolic genes (with a 
signiﬁ  cant enrichment, see Table 9), including 
fructose-1,6-bisphosphatase 1 (FBP1), glutamate 
dehydrogenase 1 (GLUD1) and acyl-Coenzyme A 
dehydrogenase (ACADSB). 
Biomarkers for Cluster B (Luminal B) 
include fibroblast growth factor FGFR4 which 
might be from the fact that this family of genes 
is known to be overexpressed in cancers of the 
cervix and bladder, though their role in breast 
cancers is more controversial (Streit et al. 2004; 
Jezequel et al. 2004); two cancer related genes: 
Gamma-glutamyl hydrolase (GGH) gene, which 
was also identified as a biomarker for pulmo-
nary neuroendocrine tumors (He et al. 2004), 
and laminin, gamma 2 (LAMC2) gene, which 
was reported to be involved in tumor invasion 
and metastases in pancreatic ductal adenocar-
cinoma (Takahashi et al. 2002) and endometrial 
adenocarcinomas (Maatta et al. 2004). The latter 
gene is down-regulated in the breast cancer data 
sets analyzed here. 
Generally, Cluster C (ERBB2+ subtype) 
biomarkers appear to be mostly receptors, receptor 
binding proteins and signal transduction related 
proteins (Table 9). As expected, the most charac-
teristic of these genes is the up-regulated ERBB2 
gene. Other important genes include two breast 
cancer related genes, namely, the F2R gene, a matrix 
metalloprotease-1 receptor that promotes invasion 
and tumorigenesis of breast cancer cells (Boire 
et al. 2005); and PPAR binding protein, coactivator 
of ESR1 and overexpressed in breast cancer (Zhu 
et al. 1999). The down-regulation of FLNB ﬁ  lamin 
B alters the MAP Kinase pathway with implications 
in both growth control and development.
The marker genes for the Basal phenotype 
(Cluster D) are significantly involved in cell 
cycle, regulation of cell proliferation, endoplasmic 
reticulum as well as in various metabolic processes. 
Important cancer related genes identiﬁ  ed for this 
phenotype are CDK6 gene, which inhibits prolif-
eration of human mammary epithelial cells (Lucas 
et al. 2004); SIAT4C, which is down-regulated in 
RCC (Saito et al. 2002), RHOB, which is known to 
be a pro-apoptotic and tumor suppressor gene, and 
the FLT1 and TFF3 gene. Plasminogen activator 
gene (PLAT) is involved in tissue remodeling while 
ﬁ  bromodulin (FMOD) gene has a primary role in 
collagen ﬁ  brillogenesis. 
The last of the clusters is the control or normal 
group. Here we ﬁ  nd that the genes identiﬁ  ed as 
signiﬁ  cant markers are involved in organelle orga-
nization and biogenesis, cytoskeleton organization 
and biogenesis, or in metabolic pathways (e.g. 
cofactor biosynthesis). These represent genes that 
are pathologically expressed in all tumor strata; 
consequently they are able to robustly stratify BCA 
samples from control (Normals).Cancer Informatics Online 2006: 2 269
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Overall, the biomarkers notably constitute genes 
that participate in breast cancer related pathways 
(e.g. marker genes involved in estrogen receptor 
pathway) and genes that were previously impli-
cated in other cancer types (e.g. GSTP1, FLT1,
see Table 8). Moreover, the enriched categories in 
each phenotype are biologically plausible, having 
already been implicated in cancer transformation 
(e.g. cell cycle, cell motility, cytoskeleton organi-
zation) (Hanahan and Weinberg, 2000) or being 
potentially important in transformation (signal 
transduction pathways, metabolism). 
Summary and Discussion
We have presented a robust clustering and pattern 
based analysis of the phenotypes identified by 
Sorlie et al. 2003. We ﬁ  nd that the clusters for 
Luminal A, Basal and Normal subtypes are homog-
enous and have predictive content. However, the 
Luminal B and ERBB2+ assignments are sensitive 
to data perturbations. One reason for this is that 
the genes chosen for the classiﬁ  cation are too few 
and not appropriate for these two categories. This 
is evidenced by the fact that the number of genes 
for Luminal B and ERBB2+ that pass our stringent 
robustness ﬁ  lters is small. Another reason is that 
hierarchical clustering is inappropriate to resolve the 
subtleties of the Luminal B and ERBB2+ categories. 
Finally, these subtypes are more heterogeneous than 
Luminal A and Basal and possibly have further 
substructure not classiﬁ  able with the genes in this 
dataset. A larger number of samples and better/more 
genes are necessary to test these conclusions. 
Several samples previously unclassified in 
Sorlie et al. 2003 were classiﬁ  able by our tech-
niques. We also found several samples which show 
a complex (multiple) phenotype signature. Given 
the treatment implications, the patients from whom 
Table 9. Enriched  GO properties for the core phenotypes.Cancer Informatics Online 2006: 2 270
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these samples were taken should undergo further 
analysis or different treatment. 
We also describe a general method to deal with 
sensitivity to noise in gene array data, which often 
confounds the analysis. There are four principal 
sources of noise. The ﬁ  rst, which we cannot do 
anything about, is the experiment itself: a) different 
samples handled differently in and experiment or 
between different labs; b) data improperly collected 
or improperly recorded/measured; c) microarray or 
cDNA readout with missing or unreliable entries. 
The second type of “noise” is stochastic noise; 
from statistical errors in the measurement of the 
signal or from normal variation within a phenotype 
in the sample population. We show how to partially 
account for this noise by data perturbations and 
consensus analysis. A third source of noise is the 
data analysis methods used. In particular, there are 
many different deﬁ  nitions of distance between gene 
expression vectors and many different clustering 
techniques. These often lead to different clusters 
depending on parameter choices, and to clusters 
that are unstable to perturbations. Our method 
robustly deals with this issue to get reliable predic-
tions. A fourth source of noise derives from the 
genes selected as the basis for the analysis (Ein-Dor 
et al. 2005). This set results both from the initial 
choice of genes on the chip and the subset of genes 
that is used in the clustering. The choice of genes 
on chips will improve only if chip manufactures 
come up with better chips, possibly motivated by 
the biology of the underlying processes. However, 
given a gene set, this paper describes a procedure to 
select a data perturbation independent and predic-
tive subset of the genes. 
The fundamental requirement of any clustering 
analysis is the assignment of conﬁ  dence levels 
to clusters. This is particularly important in gene 
expression analysis where a small sample set is clus-
tered using a large set of noisy genes which makes 
the clustering results sensitive to noise and suscep-
tible to over-ﬁ  tting. Our methods use re-sampling 
and cross validation to simulate perturbations of the 
data, and this allows us assess the stability of the 
clustering with respect to sample variability.
In functional genomics, agglomerative hierar-
chical clustering (HC) has been widely adopted as 
the unsupervised analysis tool of choice, mainly 
because of its intuitive appeal and its visualization 
properties. By not committing to a speciﬁ  c number 
of clusters, HC provides for a multi-resolution 
view of the data that can be extremely useful in 
exploratory data analysis. However, the method 
does not provide for an “objective” criterion to 
establish the number of clusters and the clusters’ 
boundaries. Furthermore, the resulting trees are 
known to be highly unstable to small perturbations 
of the data. The trees also tend to preserve sample 
joining errors made at earlier stages. 
To correct for these problems, we recommend 
averaging over perturbations of the original data. 
The hierarchical clustering algorithm can then be 
applied to each of the perturbed data sets, and the 
agreement, or consensus, among the multiple runs 
can be assessed. This technique will measure the 
“stability” of the discovered clusters to sampling 
variability. The basic assumption of the method is 
intuitively simple: if the data represent a sample 
of items drawn from distinct sub-populations, and 
if we were to observe a different sample drawn 
from the same sub populations, the induced cluster 
composition and number should not be radically 
different. Therefore, the more the attained clusters 
are robust to sampling variability, the more conﬁ  -
dent we can be that these clusters represent real 
structure. Overall, the procedures suggested here 
will be of use in examining any data in a way that 
makes the predictions insensitive to stochastic and 
systematic variation.
A frequent concern in gene-array data and 
analysis is whether the data is reproducible, and 
whether the inferences are consistent with current 
biological knowledge. In this paper we address the 
ﬁ  rst issue by applying the results of our analysis 
on one data set to make predictions on another. 
For the phenotypes which cluster well, we can 
make deﬁ  nite predictions on the unseen data. In 
addition, we identify pathways via genes whose 
markers are predictive of phenotype. It is likely that 
these genes have only diagnostic value, i.e. they 
are downstream effects of an established disease 
process whose cause is outside the identiﬁ  ed set 
of genes. This is a problem with most microarray 
data which is usually available only for cells which 
show established disease. 
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Supplementary Information 
Supplementary Information I: Multiple Testing Correction Metrics 
The general multiple hypothesis testing analysis used in our paper results in the following matrix: 
We use the following statistics to analyze this 
table. 
False discovery rate (FDR). The FDR (Benjamini 
and Hochberg 1995) is the expected proportion 
of Type I errors among the rejected hypotheses: 
FDR = E(Q); with Q = V/R if R > 0 and Q = 0; if 
R = 0. 
The q-value of a gene (Storey and Tibshirani, 
2003) is deﬁ  ned as the minimal FDR at which it 
appears signiﬁ  cant. 
Family–wise error rate (FWER, Dudoit et al. 
2003). The FWER is deﬁ  ned as the probability of 
at least one Type I error (false positive): FWER = 
Pr(V > 0)
The Bonferroni correction (Bonferroni 1935) : 
Suppose we conduct a hypothesis test for each gene 
g = 1,…,N, producing an observed test statistic: 
Tg , an unadjusted p–value: pg. = the probability 
under the null hypothesis that the test statistic is at 
least as extreme as Tg. Under the null hypothesis, 
Pr(pg < a ) = a. 
Bonferroni adjusted p–values: pg = min (1, N pg.) 
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Supplementary Information II: 
Functional class scoring 
for GO categories
We computed the statistical signiﬁ  cance of a GO 
category within a collection of N gene markers 
by following Pavlidis et al. 2004: A p-value was 
computed for each of the N marker genes in our 
collection. Next, the set of p-values was tested for 
enrichment in a GO category by using the Func-
tional Class (LS) and the Kolmogorov-Smirnov 
(KS) statistics. For a set of N genes, these are 
deﬁ  ned as
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The statistical signiﬁ  cance of a GO category with 
N genes was measured by computing the empirical 
distribution of LS and KS from 100,000 random 
selections of N genes in the complete pool of genes. 
The LS/KS permutation p-value was computed by 
comparing the LS/KS statistics in these experi-
ments to the measured value of these statistics for 
the selected genes. A GO category was considered 
enriched if its corresponding LS or KS re-sampling 
p-value was below 0.005.
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